Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HSAQ Health Sciences Acquisitions Co. 2	$3.09 -2.2%	$2.85	$9.41 ▼ $13.80	$34.65M	0.09	205,918 shs	154,220 shs
LUCD Lucid Diagnostics	$1.29 -1.5%	$1.30	$0.68 ▼ $1.80	$139.56M	1.31	586,071 shs	744,546 shs
LUNG Pulmonx	$3.03 -3.5%	$3.94	$2.83 ▼ $9.37	$121.98M	0.52	311,311 shs	179,455 shs
PDEX Pro-Dex	$39.56 -3.3%	$50.32	$16.84 ▼ $70.26	$129.01M	0.17	32,119 shs	24,785 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HSAQ Health Sciences Acquisitions Co. 2	0.00%	-6.65%	+6.92%	-24.26%	-61.23%
LUCD Lucid Diagnostics	0.00%	0.00%	+2.38%	-12.24%	+72.46%
LUNG Pulmonx	0.00%	-4.42%	-11.66%	-61.10%	-47.49%
PDEX Pro-Dex	0.00%	-7.81%	-8.26%	-19.08%	+104.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	3.2038 of 5 stars	3.6	5.0	0.0	0.0	2.2	1.7	0.6
LUNG Pulmonx	3.6625 of 5 stars	3.3	5.0	0.0	0.0	2.1	3.3	1.3
PDEX Pro-Dex	3.2133 of 5 stars	3.5	2.0	0.0	0.0	2.2	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HSAQ Health Sciences Acquisitions Co. 2	0.00	N/A	N/A	N/A
LUCD Lucid Diagnostics	3.20	Buy	$3.55	175.19% Upside
LUNG Pulmonx	2.63	Moderate Buy	$11.53	280.36% Upside
PDEX Pro-Dex	3.00	Buy	$56.00	41.56% Upside

Current Analyst Ratings Breakdown

Latest HSAQ, LUCD, LUNG, and PDEX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.50 ➝ $7.75
5/27/2025	PDEX Pro-Dex	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$54.00 ➝ $56.00
5/22/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.50 ➝ $4.15
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/1/2025	LUNG Pulmonx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/1/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00 ➝ $9.00
5/1/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
3/26/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	($0.62) per share	N/A
LUCD Lucid Diagnostics	$4.17M	33.44	N/A	N/A	($0.47) per share	-2.74
LUNG Pulmonx	$87.47M	1.39	N/A	N/A	$3.09 per share	0.98
PDEX Pro-Dex	$64.12M	2.01	$1.14 per share	34.81	$9.76 per share	4.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HSAQ Health Sciences Acquisitions Co. 2	-$380K	N/A	0.00	∞	N/A	N/A	N/A	-2.38%	N/A
LUCD Lucid Diagnostics	-$52.67M	-$1.34	N/A	N/A	N/A	-1,069.87%	N/A	-123.54%	8/11/2025 (Estimated)
LUNG Pulmonx	-$60.84M	-$1.44	N/A	N/A	N/A	-67.31%	-55.36%	-33.53%	7/30/2025 (Estimated)
PDEX Pro-Dex	$2.13M	$2.80	19.68	19.20	N/A	11.06%	21.68%	12.40%	9/4/2025 (Estimated)

Latest HSAQ, LUCD, LUNG, and PDEX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million
5/1/2025	Q3 2025	PDEX Pro-Dex	$0.47	$0.98	+$0.51	$0.98	$17.70 million	$17.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
PDEX Pro-Dex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HSAQ Health Sciences Acquisitions Co. 2	N/A	0.17	0.61
LUCD Lucid Diagnostics	N/A	1.18	1.14
LUNG Pulmonx	0.40	7.70	6.77
PDEX Pro-Dex	0.33	2.58	1.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HSAQ Health Sciences Acquisitions Co. 2	89.71%
LUCD Lucid Diagnostics	74.01%
LUNG Pulmonx	91.04%
PDEX Pro-Dex	15.28%

Insider Ownership

Company	Insider Ownership
HSAQ Health Sciences Acquisitions Co. 2	21.90%
LUCD Lucid Diagnostics	6.80%
LUNG Pulmonx	6.80%
PDEX Pro-Dex	47.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HSAQ Health Sciences Acquisitions Co. 2	4	11.21 million	8.76 million	Not Optionable
LUCD Lucid Diagnostics	70	108.19 million	54.12 million	No Data
LUNG Pulmonx	250	40.26 million	37.24 million	Optionable
PDEX Pro-Dex	140	3.26 million	1.71 million	Not Optionable

HSAQ, LUCD, LUNG, and PDEX Headlines

Recent News About These Companies

Head to Head Survey: iRhythm Technologies (NASDAQ:IRTC) versus Pro-Dex (NASDAQ:PDEX)

June 11, 2025 | americanbankingnews.com

Pro-Dex (NASDAQ:PDEX) Price Target Raised to $56.00 at Ascendiant Capital Markets

May 28, 2025 | marketbeat.com

OMERS ADMINISTRATION Corp Takes Position in Pro-Dex, Inc. (NASDAQ:PDEX)

May 22, 2025 | marketbeat.com

Are Pro-Dex, Inc.'s (NASDAQ:PDEX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

May 20, 2025 | finance.yahoo.com

Pro-Dex: Crash After Strong Earnings Leads To A Buying Opportunity

May 5, 2025 | seekingalpha.com

Here's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of Investors

May 4, 2025 | uk.finance.yahoo.com

Pro-Dex, Inc. (PDEX) Q3 Earnings Surpass Estimates

May 1, 2025 | zacks.com

Pro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month Results

May 1, 2025 | accessnewswire.com

ProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?

April 25, 2025 | zacks.com

Take the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in Focus

April 21, 2025 | zacks.com

ProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?

April 3, 2025 | zacks.com

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 842 Shares

April 2, 2025 | insidertrades.com

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 836 Shares

April 1, 2025 | insidertrades.com

Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 3,096 Shares of Stock

March 28, 2025 | insidertrades.com

Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 5,151 Shares of Stock

March 18, 2025 | insidertrades.com

With 38% ownership in Pro-Dex, Inc. (NASDAQ:PDEX), hedge funds investors have a lot riding on the business

March 11, 2025 | finance.yahoo.com

ProDex (PDEX) Upgraded to Strong Buy: Here's What You Should Know

February 28, 2025 | zacks.com

(PDEX) Investment Report

February 8, 2025 | news.stocktradersdaily.com

Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 1,100 Shares of Stock

February 4, 2025 | insidertrades.com

Pro-Dex, Inc. Reports Strong Q2 Growth in 2025

January 30, 2025 | tipranks.com

Pro-Dex, Inc. (PDEX) Surpasses Q2 Earnings and Revenue Estimates

January 30, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSAQ, LUCD, LUNG, and PDEX Company Descriptions

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

$3.09 -0.07 (-2.22%)

As of 06/13/2025

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

Lucid Diagnostics NASDAQ:LUCD

$1.29 -0.02 (-1.53%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.00 (+0.39%)

As of 06/13/2025 07:24 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Pulmonx NASDAQ:LUNG

$3.03 -0.11 (-3.50%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.06 +0.03 (+0.83%)

As of 06/13/2025 07:33 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Pro-Dex NASDAQ:PDEX

$39.56 -1.36 (-3.32%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$39.79 +0.23 (+0.58%)

As of 06/13/2025 04:04 PM Eastern

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time